Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
IMDX Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: June 09, 2026
Report Source: 2026 1st Quarter Report
Insight Molecular Diagnostics Inc. Stock Analysis IMDX
United States Health Care Micro Cap Report: Insight Molecular Diagnostics, Inc. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. The company is headquartered in Nashville, Tennessee and currently employs 55 full-time employees. The company went IPO on 2015-12-30. The firm's technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). The company is in the process of rebranding its VitaGraft assay (also known as VitaGraft Kidney), which is a lab developed test, under the name GraftAssureCore. The firm's transplant products include GraftAssureCore, GraftAssureDx, GraftAssureIQ. Its oncology products include DetermaCNI, DetermaIO, and OncoTIME. GraftAssureCore is a clinical blood-based solid organ transplantation monitoring test. GraftAssureIQ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. OncoTIME enables research on the tumor immune microenvironment.
Read More Insight Molecular Diagnostics Inc (IMDX) Chart
Key Statistics of Insight Molecular Diagnostics Inc (IMDX)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$5.36Volume
119.81KP/E Ratio (TTM)
-52 Week Range
Market Cap
189.87MAvg. Volume
285.12KDividend Yield
-Financial Metrics & Statements of Insight Molecular Diagnostics Inc (IMDX)
FAQ's for Insight Molecular Diagnostics Inc (IMDX)
- According to Musaffa’s Shariah screening methodology, Insight Molecular Diagnostics Inc (IMDX) is currently classified as NOT HALAL as of June 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Insight Molecular Diagnostics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Insight Molecular Diagnostics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Insight Molecular Diagnostics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Insight Molecular Diagnostics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Insight Molecular Diagnostics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.